OTIC Otonomy, Inc. Stock Quote

OTIC [NASD]

Index	-	P/E	-	EPS (ttm)	-0.78	Insider Own	1.60%	Shs Outstand	67.85M	Perf Week	12.79%
Market Cap	107.30M	Forward P/E	-	EPS next Y	-0.77	Insider Trans	-4.22%	Shs Float	55.75M	Perf Month	-15.28%
Income	-52.50M	PEG	-	EPS next Q	-0.20	Inst Own	64.00%	Short Float	0.91%	Perf Quarter	-4.43%
Sales	0.12M	P/S	858.41	EPS this Y	26.30%	Inst Trans	-0.10%	Short Ratio	3.13	Perf Half Y	-9.77%
Book/sh	0.64	P/B	3.03	EPS next Y	3.80%	ROA	-52.90%	Target Price	6.50	Perf Year	-17.09%
Cash/sh	-	P/C	-	EPS next 5Y	20.40%	ROE	-86.70%	52W Range	1.14 - 2.59	Perf YTD	-6.73%
Dividend	-	P/FCF	-	EPS past 5Y	26.20%	ROI	-69.70%	52W High	-25.09%	Beta	1.70
Dividend %	-	Quick Ratio	-	Sales past 5Y	-28.80%	Gross Margin	-	52W Low	70.18%	ATR	0.21
Employees	51	Current Ratio	6.60	Sales Q/Q	-100.00%	Oper. Margin	-	RSI (14)	43.26	Volatility	13.94% 10.64%
Optionable	Yes	Debt/Eq	0.38	EPS Q/Q	14.40%	Profit Margin	-	Rel Volume	0.46	Prev Close	1.87
Shortable	Yes	LT Debt/Eq	0.37	Earnings	May 09 AMC	Payout	-	Avg Volume	161.40K	Price	1.94
Recom	1.80	SMA20	-9.23%	SMA50	-13.84%	SMA200	-3.07%	Volume	74,796	Change	3.74%

Jun-01-20

Resumed

Oppenheimer

Outperform

Dec-24-19

Initiated

Oppenheimer

Outperform

Mar-19-18

Downgrade

JP Morgan

Neutral → Underweight

Mar-12-18

Upgrade

Piper Jaffray

Neutral → Overweight

Aug-30-17

Downgrade

Piper Jaffray

Overweight → Neutral

Aug-30-17

Downgrade

JP Morgan

Overweight → Neutral

Aug-15-17

Upgrade

JP Morgan

Neutral → Overweight

Jun-02-17

Initiated

Piper Jaffray

Overweight

$32

May-26-16

Initiated

WallachBeth

Buy

$29

Aug-10-15

Upgrade

Bernstein

Mkt Perform → Outperform

May-22-15

Downgrade

JP Morgan

Overweight → Neutral

May-18-22 07:30AM	Otonomy to Participate in the H.C. Wainwright Global Investment Conference GlobeNewswire -5.56%
May-12-22 07:30AM	Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting GlobeNewswire
May-09-22 09:00PM	Otonomy (OTIC) Q1 2022 Earnings Call Transcript Motley Fool
04:04PM	Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire
May-02-22 07:30AM	Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update GlobeNewswire
Apr-20-22 11:12AM	Otonomy Hearing Loss Candidate Shows Clinical Benefit On Multiple Efficacy Endpoints Benzinga +5.53%
07:30AM	Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss GlobeNewswire
Mar-21-22 06:51PM	Here's What Otonomy, Inc.'s (NASDAQ:OTIC) Shareholder Ownership Structure Looks Like Simply Wall St.
Mar-15-22 07:30AM	Otonomy to Host Virtual Investor R&D Event on March 22, 2022 GlobeNewswire
Feb-28-22 09:00PM	Otonomy (OTIC) Q4 2021 Earnings Call Transcript Motley Fool
04:27PM	Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update GlobeNewswire
07:30AM	Otonomy to Participate in Two Upcoming Investor Conferences GlobeNewswire
Feb-25-22 07:30AM	Otonomy to Host Virtual Investor R&D Event on March 22, 2022 GlobeNewswire
Feb-22-22 07:30AM	Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus GlobeNewswire
Feb-17-22 07:30AM	Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update GlobeNewswire
Feb-16-22 07:30AM	Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting GlobeNewswire
Jan-25-22 07:30AM	Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting GlobeNewswire
Jan-06-22 07:51AM	Otonomy Reports Corporate and Product Pipeline Update GlobeNewswire
Jan-03-22 07:30AM	Otonomy to Participate in the H.C. Wainwright BioConnect Conference GlobeNewswire
Nov-16-21 07:30AM	Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference GlobeNewswire
Nov-10-21 07:05PM	Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:18PM	Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-03-21 07:30AM	Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update GlobeNewswire
Oct-27-21 03:03PM	Otonomy (OTIC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
07:30AM	Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting GlobeNewswire
Oct-12-21 07:30AM	Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313 GlobeNewswire
Sep-27-21 07:30AM	Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting GlobeNewswire +10.23%
Sep-22-21 09:08AM	What Is The Ownership Structure Like For Otonomy, Inc. (NASDAQ:OTIC)? Simply Wall St.
Sep-02-21 07:30AM	Otonomy to Participate in Two Upcoming Investor Conferences GlobeNewswire
Aug-19-21 07:30AM	Otonomy Appoints Jill Broadfoot to Board of Directors GlobeNewswire -14.08%
Aug-04-21 06:45PM	Otonomy (OTIC) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:16PM	Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Jul-28-21 07:30AM	Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update GlobeNewswire
Jul-27-21 03:03PM	Will Otonomy (OTIC) Report Negative Q2 Earnings? What You Should Know Zacks
Jun-16-21 02:05AM	Increases to CEO Compensation Might Be Put On Hold For Now at Otonomy, Inc. (NASDAQ:OTIC) Simply Wall St.
Jun-15-21 07:30AM	Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss GlobeNewswire
May-14-21 02:59PM	Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows Benzinga
07:30AM	Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting GlobeNewswire
May-11-21 04:17PM	Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Otonomy, Inc. to Host Earnings Call ACCESSWIRE
May-04-21 07:30AM	Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update GlobeNewswire -5.00%
Apr-28-21 07:30AM	Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting GlobeNewswire +5.11%
Apr-19-21 07:30AM	Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +5.43%
Apr-07-21 10:02PM	Otonomy Announces Pricing of $30.1 Million Public Offering GlobeNewswire
04:06PM	Otonomy Announces Proposed Public Offering GlobeNewswire
Apr-06-21 07:30AM	Otonomy to Present at the Needham Virtual Healthcare Conference GlobeNewswire
Apr-05-21 07:30AM	Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting GlobeNewswire
Mar-25-21 07:30AM	Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus GlobeNewswire
Feb-26-21 11:01AM	Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock? Zacks
Feb-25-21 07:30AM	Otonomy to Participate in Three Upcoming Investor Conferences GlobeNewswire
Feb-22-21 09:32AM	ROCE Insights For Otonomy Benzinga -44.34%
08:37AM	Otonomy stock loses half its value after disappointing trial results of vertigo treatment MarketWatch
07:23AM	Otonomy's OTIVIDEX Fails To Separate From Placebo In Inner Ear Disorder Study Benzinga
07:00AM	Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease GlobeNewswire
Feb-17-21 07:30AM	Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting GlobeNewswire +8.48%
Feb-12-21 01:31AM	Otonomy (OTIC) Q4 2020 Earnings Call Transcript Motley Fool
Feb-11-21 04:17PM	Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Otonomy, Inc. to Host Earnings Call ACCESSWIRE
Feb-04-21 07:30AM	Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update GlobeNewswire +14.26%
04:22AM	Is Otonomy (NASDAQ:OTIC) Weighed On By Its Debt Load? Simply Wall St.
Jan-05-21 07:30AM	Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference GlobeNewswire
Dec-17-20 07:00AM	Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss GlobeNewswire +7.36%
Dec-15-20 07:50PM	Is OTIC A Good Stock To Buy Now? Insider Monkey +5.77%
Dec-14-20 08:59AM	Otonomy (OTIC) Looks Good: Stock Adds 5% in Session Zacks
Nov-30-20 07:30AM	Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs GlobeNewswire
Nov-16-20 07:30AM	Otonomy to Participate in Two Upcoming Investor Conferences GlobeNewswire
Nov-06-20 09:03AM	Otonomy, Inc. (NASDAQ:OTIC) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates Simply Wall St.
Nov-04-20 06:55PM	Otonomy (OTIC) Reports Q3 Loss, Misses Revenue Estimates Zacks
05:03PM	Otonomy: Q3 Earnings Insights Benzinga
04:17PM	Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Otonomy, Inc. to Host Earnings Call ACCESSWIRE
Oct-28-20 07:30AM	Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire
Oct-02-20 07:30AM	Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX® in Ménières Disease GlobeNewswire +6.22%
Sep-15-20 08:52AM	What Kind Of Shareholders Hold The Majority In Otonomy, Inc.'s (NASDAQ:OTIC) Shares? Simply Wall St.
Sep-10-20 08:41AM	Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock? Zacks
Sep-02-20 07:30AM	Otonomy to Participate in Four Upcoming Investor Conferences GlobeNewswire
Aug-17-20 03:30PM	Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks TipRanks +11.31%
Aug-04-20 07:25PM	Otonomy (OTIC) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:22PM	Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-20 07:30AM	Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program GlobeNewswire
Jul-28-20 04:05PM	Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire
Jul-15-20 01:15PM	Steven Cohen Homes in on Otonomy GuruFocus.com +6.62%
Jul-13-20 04:01PM	Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -7.38%
09:08AM	Otonomy (OTIC) Catches Eye: Stock Jumps 9.1% Zacks
Jul-09-20 09:00AM	Otonomy Announces Pricing of $60.1 Million Public Offering GlobeNewswire +8.15%
Jul-08-20 09:01PM	Otonomy Announces Proposed Public Offering GlobeNewswire
Jul-07-20 10:44AM	Why Otonomy's Stock Is Trading Higher Today Benzinga +11.95%
05:51AM	Otonomy Pops 15% in Pre-Market Fueled By Otividex Data, Positive Results From Tinnitus Candidate SmarterAnalyst
Jul-06-20 04:04PM	Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus GlobeNewswire
04:02PM	Otonomy Provides Update on OTIVIDEX® Program GlobeNewswire
Jun-30-20 11:42PM	Were Hedge Funds Right About Piling Into Otonomy Inc (OTIC)? Insider Monkey -5.73%
Jun-17-20 08:31AM	Analysts Are Betting On Otonomy, Inc. (NASDAQ:OTIC) With A Big Upgrade This Week Simply Wall St.
Jun-15-20 04:05PM	Otonomy Provides Update on Clinical Trials and Development Programs GlobeNewswire
Jun-11-20 08:41AM	Otonomy (OTIC) in Focus: Stock Moves 6.1% Higher Zacks -9.09%
07:30AM	Otonomy to Present at Raymond James 2020 Human Health Innovation Conference GlobeNewswire
Jun-10-20 07:30AM	Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020 GlobeNewswire +6.11%
Jun-08-20 07:30AM	Otonomy to Host Pipeline Program Update Conference Call and Webcast GlobeNewswire +6.44%
Jun-01-20 09:56AM	3 Strong Buy Biotech Stocks Under $5 With Major Catalysts Approaching TipRanks
May-28-20 08:32AM	Health Check: How Prudently Does Otonomy (NASDAQ:OTIC) Use Debt? Simply Wall St.
May-12-20 08:00AM	Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program GlobeNewswire

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Meniere's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cayer Paul E	Ch. Financial & Business Offcr	Mar 28	Sale	2.41	5,624	13,571	223,787	Mar 29 08:53 PM
Foster Alan Charles	Chief Scientific Officer	Mar 28	Sale	2.41	2,559	6,175	177,017	Mar 29 08:54 PM
Savel Robert Michael II	Chief Technical Officer	Mar 28	Sale	2.41	3,325	8,023	145,735	Mar 29 08:58 PM
Weber David Allen	President & CEO	Mar 28	Sale	2.41	11,243	27,129	377,499	Mar 29 08:59 PM
Weber David Allen	President & CEO	Mar 25	Sale	2.39	8,026	19,166	388,742	Mar 29 08:59 PM
Savel Robert Michael II	Chief Technical Officer	Mar 25	Sale	2.39	2,374	5,669	149,060	Mar 29 08:58 PM
Foster Alan Charles	Chief Scientific Officer	Mar 25	Sale	2.39	1,827	4,363	179,576	Mar 29 08:54 PM
Cayer Paul E	Ch. Financial & Business Offcr	Mar 25	Sale	2.39	4,015	9,588	229,411	Mar 29 08:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience